A Multiple Center, Randomised, Parallel Group, Single-blind Clinical Trial, to Assess the Therapeutic Equivalence in Terms of Efficacy and Safety of Test Product (Levosert) and Reference Product (Mirena) in Patients With Menorrhagia - Phase III (Therapeutic Equivalence).
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Levonorgestrel (Primary)
- Indications Menorrhagia
- Focus Registrational; Therapeutic Use
- Acronyms LVS-20
- Sponsors Uteron Pharma
- 08 Oct 2012 New trial record